Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.

Jones TD, Hearn AR, Holgate RG, Kozub D, Fogg MH, Carr FJ, Baker MP, Lacadena J, Gehlsen KR.

Protein Eng Des Sel. 2016 Aug 29. [Epub ahead of print]

2.

Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.

Ahmadi M, Bryson CJ, Cloake EA, Welch K, Filipe V, Romeijn S, Hawe A, Jiskoot W, Baker MP, Fogg MH.

Pharm Res. 2015 Apr;32(4):1383-94. doi: 10.1007/s11095-014-1541-x.

PMID:
25319104
3.

Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Leskowitz R, Fogg MH, Zhou XY, Kaur A, Silveira EL, Villinger F, Lieberman PM, Wang F, Ertl HC.

J Virol. 2014 May;88(9):4721-35. doi: 10.1128/JVI.03744-13. Epub 2014 Feb 12.

4.

Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques.

Silveira EL, Fogg MH, Leskowitz RM, Ertl HC, Wiseman RW, O'Connor DH, Lieberman P, Wang F, Villinger F.

J Virol. 2013 Dec;87(24):13904-10. doi: 10.1128/JVI.01947-13. Epub 2013 Oct 2.

5.

CD4+ and CD8+ T-cell responses to latent antigen EBNA-1 and lytic antigen BZLF-1 during persistent lymphocryptovirus infection of rhesus macaques.

Leskowitz RM, Zhou XY, Villinger F, Fogg MH, Kaur A, Lieberman PM, Wang F, Ertl HC.

J Virol. 2013 Aug;87(15):8351-62. doi: 10.1128/JVI.00852-13. Epub 2013 May 22.

6.

An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection.

Ohashi M, Fogg MH, Orlova N, Quink C, Wang F.

PLoS Pathog. 2012 Dec;8(12):e1003095. doi: 10.1371/journal.ppat.1003095. Epub 2012 Dec 27.

7.
8.

Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.

Orlova N, Fogg MH, Carville A, Wang F.

Clin Vaccine Immunol. 2011 Sep;18(9):1427-34. doi: 10.1128/CVI.05126-11. Epub 2011 Jul 6.

9.

Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.

Fogg MH, Wirth LJ, Posner M, Wang F.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3318-23. doi: 10.1073/pnas.0813320106. Epub 2009 Feb 11.

10.

Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes.

Tellam J, Fogg MH, Rist M, Connolly G, Tscharke D, Webb N, Heslop L, Wang F, Khanna R.

J Exp Med. 2007 Mar 19;204(3):525-32. Epub 2007 Feb 20.

11.
13.

Reduced prevalence of Epstein-Barr virus-related lymphocryptovirus infection in sera from a new world primate.

Fogg MH, Carville A, Cameron J, Quink C, Wang F.

J Virol. 2005 Aug;79(15):10069-72.

14.

Poliovirus proteins induce membrane association of GTPase ADP-ribosylation factor.

Belov GA, Fogg MH, Ehrenfeld E.

J Virol. 2005 Jun;79(11):7207-16.

15.
16.

Isolation of enzymatically active replication complexes from feline calicivirus-infected cells.

Green KY, Mory A, Fogg MH, Weisberg A, Belliot G, Wagner M, Mitra T, Ehrenfeld E, Cameron CE, Sosnovtsev SV.

J Virol. 2002 Sep;76(17):8582-95.

17.

Supplemental Content

Support Center